Efficacy of iron-folic acid treatment for reducing anemia prevalence and improving iron status in women of reproductive age: A one-year longitudinal study. (June 2022)

• Record Type: Journal Article
• Authors: Palika, Ravindranadh; Dasi, Teena; Ghosh, Santu; Peter, Rajini; Parasannanavar, Devraj J.; Pradhan, Anju Sinha; Kurpad, Anura V.; Sachdev, Harshpal Singh; Kulkarni, Bharati; Pullakhandam, Raghu
• Is Part Of: Clinical nutrition ESPEN. Volume 49(2022)
• Page Start: 390
• Page End: 397
• Publication Date: 2022-06
• Subjects: Iron-folic acid -- Anemia -- Hemoglobin -- Iron status -- Ferritin -- Follow up; Nutritionally induced diseases -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39005
• DOI: 10.1016/j.clnesp.2022.03.016
• Languages: English
• ISSNs: 2405-4577

Abstract

Summary: Background: Anemia control has hitherto been through prophylaxis with weekly iron folic acid (IFA) in Indian women of reproductive age (WRA). Recently, a more precise approach has been proposed, that uses a 'screen and treat with IFA' approach for anemic WRA, combined with continued prophylactic IFA in non-anemic WRA. The efficacy of this approach was assessed in Indian WRA, along with changes in iron status biomarkers. Methods: Young WRA (n = 470), aged 17-21 y, were screened for their venous blood hemoglobin (Hb) and treated with IFA for 90 days according to their grade of anemia, or if non-anemic, administered prophylactic IFA, per Indian policy guidelines, and then followed-up for an additional 9-months. Their Hb, plasma ferritin (PF), transferrin receptor, hepcidin and C-reactive protein concentrations were measured at baseline, during treatment and further follow-up. Anemia was diagnosed using Hb (<12 g/dL) and iron deficiency (ID) using PF (<15 μg/L) cut-offs after adjustment for inflammation. Co-existence of anemia and ID was labelled iron deficiency anemia (IDA). Results: At baseline, in the whole group anemia, ID and IDA prevalence was 69.6%, 68.7% and 62.4%, respectively. At 90 days, IFA treatment or prophylaxis significantly reduced anemia by 40 percentage points (pp), from 69.6% at baseline to 29.8%; ID by 47.3 pp, and IDA by 48 pp. Moreover, significant treatment effects persisted at 365 days of follow-up. Conclusion: The 'screen and treat with IFA' approach is efficacious in reducing the prevalence of anemia in general among WRA, with persistent and significant effects after 9 months of follow-up. Trail registration: CTRI No:2019/02/017806, http://ctri.nic.in/